Management of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics

References

• DeConde AS, Soler ZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30(2):134–139. doi:10.2500/ajra.2016.30.4297
   PubMed Web of Science ®Google Scholar
• Ahn JC, Kim JW, Lee CH, Rhee CS. Prevalence and risk factors of chronic rhinosinusitus, allergic rhinitis, and nasal septal deviation results of the Korean national health and nutrition survey 2008–2012. JAMA Otolaryngol Head Neck Surg. 2016;142(2):162–167. doi:10.1001/jamaoto.2015.3142
   PubMed Web of Science ®Google Scholar
• Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739. doi:10.1002/alr.22741
   PubMed Web of Science ®Google Scholar
• Soler ZM, Sauer D, Mace J, Smith TL. Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after sinus surgery. Otolaryngol Head Neck Surg. 2010;142(1):64–71. doi:10.1016/j.otohns.2009.10.005
   PubMed Web of Science ®Google Scholar
• Katotomichelakis M, Simopoulos E, Zhang N, et al. Olfactory dysfunction and asthma as risk factors for poor quality of life in upper airway diseases. Am J Rhinol Allergy. 2013;27(4):293–298. doi:10.2500/ajra.2013.27.3903
   Web of Science ®Google Scholar
• Erskine SE, Hopkins C, Clark A, et al. Chronic rhinosinusitis and mood disturbance. Rhinol J. 2017;55(2):113–119. doi:10.4193/rhin16.111
   PubMed Web of Science ®Google Scholar
• Tomoum MO, Klattcromwell C, Delsignore A, Ebert C, Senior BA. Depression and anxiety in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015;5(8):674–681. doi:10.1002/alr.21528
   Web of Science ®Google Scholar
• Litvack JR, Mace J, Smith TL. Role of depression in outcomes of endoscopic sinus surgery. Otolaryngol Head Neck Surg. 2011;144(3):446–451. doi:10.1177/0194599810391625
   Web of Science ®Google Scholar
• Turner JH, Li P, Chandra RK. Mucus T helper 2 biomarkers predict chronic rhinosinusitis disease severity and prior surgical intervention. Int Forum Allergy Rhinol. 2018;8(10):1175–1183. doi:10.1002/alr.22160
   PubMed Web of Science ®Google Scholar
• Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012;129(6):1522–1528.e5. doi:10.1016/j.jaci.2012.01.079
   PubMed Web of Science ®Google Scholar
• Turner JH, Chandra RK, Li P, Bonnet KSD. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018;141(5):1895–7.
   PubMed Web of Science ®Google Scholar
• Chapurin N, Li P, Chandra RK, Turner JH, Chowdhury NI. Elevated mucus interleukin-17A levels are associated with increased prior sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2021;11(2):120–127. doi:10.1002/alr.22652
   Web of Science ®Google Scholar
• Smith TL, Schlosser RJ, Soler ZM, et al. Olfactory cleft mucus inflammatory proteins in CRS: a Case-Control Study. Int Forum Allergy Rhinol. 2021. doi:10.1002/alr.22770
   Web of Science ®Google Scholar
• Morse JC, Li P, Ely KA, et al. Chronic rhinosinusitis in elderly patients is associated with an exaggerated neutrophilic proinflammatory response to pathogenic bacteria. J Allergy Clin Immunol. 2019;143(3):990–1002.e6. doi:10.1016/j.jaci.2018.10.056
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a Multicenter Study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353. doi:10.1016/j.jaci.2016.05.041
   PubMed Web of Science ®Google Scholar
• Scott WC, Cahill KN, Milne GL, et al. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020;147(4):1318–1328.e5. doi:10.1016/j.jaci.2020.11.001
   Web of Science ®Google Scholar
• Meng J, Zhou P, Liu Y, et al. The development of nasal polyp disease involves early nasal mucosal inflammation and remodelling. PLoS One. 2013;8(12):e82373. doi:10.1371/journal.pone.0082373
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Ann Rev Pathol Mech Dis. 2017;12(1):331–357. doi:10.1146/annurev-pathol-052016-100401
   PubMed Web of Science ®Google Scholar
• Ho J, Bailey M, Zaunders J, et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy. 2015;45(2):394–403. doi:10.1111/cea.12462
   PubMed Web of Science ®Google Scholar
• Nonaka M, Ogihara N, Fukumoto A, et al. Synergistic induction of macrophage inflammatory protein-3α/CCL20 production by interleukin-17A and tumor necrosis factor-αin nasal polyp fibroblasts. World Allergy Organ J. 2009;2(10):218–223. doi:10.1097/wox.0b013e3181bdd219
   Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(SupplS29):1–464. doi:10.4193/Rhin20.600
   Google Scholar
• Lam K, Kern RC, Luong A. Is there a future for biologics in the management of chronic rhinosinusitis? Int Forum Allergy Rhinol. 2016;6(9):935–942. doi:10.1002/alr.21780
   PubMed Web of Science ®Google Scholar
• Stevens WW, Schleimer RP. Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis. Immunol Allergy Clin North Am. 2016;36(4):669–680. doi:10.1016/j.iac.2016.06.004
   Web of Science ®Google Scholar
• Morse JC, Shilts MH, Ely KA, et al. Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms. Int Forum Allergy Rhinol. 2019;9(3):255–264. doi:10.1002/alr.22249
   PubMed Web of Science ®Google Scholar
• Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192(6):682–694. doi:10.1164/rccm.201412-2278OC
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):326–332. doi:10.1016/j.anai.2019.12.001
   PubMed Web of Science ®Google Scholar
• Chang CC. Sinusitis, rhinitis, asthma, and the single airway hypothesis. In: Diseases of the Sinuses. New York: Springer;2014:173–194. doi:10.1007/978-1-4939-0265-1_11
   Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Scangas GA, Wu AW, Ting JY, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021;131(1):E26–E33. doi:10.1002/lary.28648
   PubMed Web of Science ®Google Scholar
• Brown WC, Senior B, Critical A. Look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep. 2020;20(6). doi:10.1007/s11882-020-00910-y
   Web of Science ®Google Scholar
• Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL. Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. Laryngoscope. 2015;125(1):25–32. doi:10.1002/lary.24916
   PubMed Web of Science ®Google Scholar
• Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. Laryngoscope. 2017;127(1):29–37. doi:10.1002/lary.26169
   PubMed Web of Science ®Google Scholar
• Anderson WC, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372. doi:10.1016/j.anai.2019.01.018
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:10.1016/j.anai.2016.10.028
   PubMed Web of Science ®Google Scholar
• Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872–881. doi:10.1080/02770903.2018.1500584
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–582. doi:10.7326/0003-4819-154-9-201105030-00002
   PubMed Web of Science ®Google Scholar
• Doroudchi A, Pathria M, Modena BD. Asthma biologics: comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol. 2020;124(1):44–56. doi:10.1016/j.anai.2019.10.016
   PubMed Web of Science ®Google Scholar
• Zhang N, Holtappels G, Gevaert P, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy Eur J Allergy Clin Immunol. 2011;66(1):141–148. doi:10.1111/j.1398-9995.2010.02448.x
   Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.e1. doi:10.1016/j.jaci.2012.07.047
   PubMed Web of Science ®Google Scholar
• Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinol J. 2010;48(3):318–324. doi:10.4193/rhin09.144
   PubMed Web of Science ®Google Scholar
• Rivero A, Liang J. Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis. Ann Otol Rhinol Laryngol. 2017;126(11):739–747. doi:10.1177/0003489417731782
   PubMed Web of Science ®Google Scholar
• Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinol J. 2018;56(1):42–45. doi:10.4193/rhin17.139
   PubMed Web of Science ®Google Scholar
• Kim H, Ellis AK, Fischer D, et al. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol. 2017;13(1). doi:10.1186/s13223-017-0219-4
   Web of Science ®Google Scholar
• Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192–198. doi:10.2500/ajra.2014.28.4033
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/nejmoa1403290
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.e14. doi:10.1016/j.jaci.2017.05.044
   PubMed Web of Science ®Google Scholar
• Lee S, Tabberer M, Trigg A, et al. Mepolizumab improves health related quality of life for patients with chronic rhinosinusitis with nasal polyps: data from the SYNAPSE Study. J Allergy Clin Immunol. 2021;147(2):AB125. doi:10.1016/j.jaci.2020.12.458
   Web of Science ®Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–118. doi:10.1517/14712598.2012.642359
   PubMed Web of Science ®Google Scholar
• Matsuno O, Minamoto S. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps. Pulm Pharmacol Ther. 2020;64:101965. doi:10.1016/j.pupt.2020.101965
   Web of Science ®Google Scholar
• Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:205873842095085. doi:10.1177/2058738420950851
   Web of Science ®Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51(6):836–844. doi:10.1111/cea.13852
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet L-P, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/nejmoa1402895
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi:10.1056/nejmoa1704064
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593–600.e12. doi:10.1016/j.jaci.2013.04.005
   PubMed Web of Science ®Google Scholar
• Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010;185(6):3472–3480. doi:10.4049/jimmunol.1000730
   PubMed Web of Science ®Google Scholar
• Kim DK, Jin HR, Eun KM, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72(7):635–645. doi:10.1136/thoraxjnl-2016-208772
   PubMed Web of Science ®Google Scholar
• Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene–driven IL-33–mediated mast cell activation pathway. J Immunol. 2015;195(8):3537–3545. doi:10.4049/jimmunol.1500905
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Gao Y, et al. Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma. Rhinology. 2020;58(2):126–135. doi:10.4193/rhin19.184
   PubMed Web of Science ®Google Scholar
• Soler ZM, Jones R, Le P, et al. Sino-nasal outcome test-22 outcomes after sinus surgery: a systematic review and meta-analysis. Laryngoscope. 2018;128(3):581–592. doi:10.1002/lary.27008
   Web of Science ®Google Scholar
• Smith TL, Schlosser RJ, Mace JC, et al. Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(8):831–841. doi:10.1002/alr.22369
   Web of Science ®Google Scholar
• Gurrola J, Borish L. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. J Allergy Clin Immunol. 2017;140(6):1499–1508. doi:10.1016/j.jaci.2017.10.006
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e4. doi:10.1016/j.jaci.2015.12.1324
   PubMed Web of Science ®Google Scholar